Is Evotec SE halal to invest in?

As of August 2026, Evotec SE EVT.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Evotec SE a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Evotec SE using these criteria to determine its compliance status.

Can Muslims buy shares of Evotec SE?

Muslim investors may consider investing in Evotec SE if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Evotec SE classified as HALAL?

Musaffa determines the Shariah status of Evotec SE by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Evotec SE updated?

The Shariah compliance status of Evotec SE may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Evotec SE become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Evotec SE?

You can check the latest Shariah compliance status of Evotec SE on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Evotec SE EVT.VI

Last Updated: Aug 14, 12:00 AM·WBAG

EVT.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Evotec SE is classified as halal.

HALAL

Report Source: undefined Quarter Report

Evotec SE. Stock Analysis EVT.VI

Austria Health Care Small Cap

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.